A Double-Blind Randomized Pilot Study Evaluating the Safety and Efficacy of Topical MEP in the Facial Appearance Improvement of Estrogen Deficient Females

November 2018 | Volume 17 | Issue 11 | Original Article | 1186 | Copyright © November 2018


Zoe Diana Draelos MD

Dermatology Consulting Services, PLLC, High Point, NC

CONCLUSION

This vehicle-controlled double-blinded study demonstrated the safety, tolerability, and efficacy of MEP, a topical soft estrogen cosmeceutical for the treatment of EDS and the improvement of facial appearance without systemic effects. Investigator noted improvements in facial skin dryness, laxity, and dullness and subject noted improvements in facial fine lines and atrophy after 14 weeks of twice daily application are consistent with the histologic observation of increased estrogen receptors. Absent any other known mode of action of MEP, it is presumably the estrogen receptor binding activity of MEP that accounted for these findings. This novel ingredient uniquely addresses appearance issues common in estrogen deficient females.

DISCLOSURES

Dr. Draelos received a grant from Ferndale Pharma Group to conduct this research.

REFERENCES

  1. Draelos ZD. Topical and oral estrogen revisited for antiaging purposes. Fertil Steril. 2005;84(2):291-2.
  2. Brincat MP, Baron M, Galea R. Estrogens and the skin. Climacteric. 2005;8:110-23
  3. Emmerson E, Hardman MJ. The role of estrogen deficiency
  4. Nelson LR, Bulun SE: Estrogen production and action. J Am Acad Dermatol. 2001;45:S116-S124.
  5. Affinito P, Palomba S, Sorrention C. Di Carlo C, Bifulco G, Arienzo MP, Nappi C. Effects of postmenopausal hypoestorgenism of skin collagen. Maturitas. 1999;3:239-47.
  6. Chen L, Dyson M, Rymer J, Bolton PA, Young SR: The use of high-frequency diagnostic ultrasound to investigate the effect of hormone replacement therapy on skin thickness. Skin Res Technol. 2001;7:95-7.
  7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stenick ML, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288:321-3.
  8. Hall G, Phillips TJ: Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol. 2005;53:555-68
  9. Brincat MP: Hormone replacement therapy and the skin. Maturitas. 2000;35:107-17.
  10. US Patent 6,476,012 Hochenberg November 5, 2002.
  11. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y: Skin aging and menopause. Am J Dermatol. 2003;4(6):371-8.
  12. Thornton MJ: The biological actions of estrogen on skin. Exp Dermatol. 2002;11:487-502.
  13. Archer DF. Postmenopausal skin and estrogen. Gynecol Endocrino. 2012;28(S2):2-6.
  14. Thornton MJ: Estrogens and aging skin. Dermato-Endcrinology. 2013;5(2): 264-70.

AUTHOR CORRESPONDENCE

Zoe Diana Draelos MD zdraelos@northstate.net
Close Menu